Abstract | Background: Methods: Results: In our study cohort of 6151 IBD patients (38.4% UC), 37 168 IV iron infusions were given (median, 3 infusions). There were very few adverse events; only 1.3% of IBD patients experienced any adverse reaction. The incident rate per 1000 infusions for any adverse event among IBD patients was highest among those receiving ferumoxytol (2.54, 95% confidence interval [CI], 1.26-5.11), ferric gluconate (1.85; 95% CI, 1.03-3.35), iron sucrose (1.74; 95% CI, 1.09-2.78), and iron dextran (0.96; 95% CI, 0.43-2.13). There were 0.24 anaphylactic shock events per 1000 IV iron infusions. Conclusions: About 1.3 of 100 IBD patients ever developed any adverse event. Because adverse reactions are rare, physicians should be encouraged to adhere to recommended guidelines for iron replacement among anemic IBD patients. 10.1093/ibd/izy063_video1izy063.video15768853346001.
|
Authors | Eboselume Akhuemonkhan, Alyssa Parian, Kathryn A Carson, Susan Hutfless |
Journal | Inflammatory bowel diseases
(Inflamm Bowel Dis)
Vol. 24
Issue 8
Pg. 1801-1807
(07 12 2018)
ISSN: 1536-4844 [Electronic] England |
PMID | 29669068
(Publication Type: Journal Article, Video-Audio Media)
|
Chemical References |
- Ferric Compounds
- ferric gluconate
- Ferrosoferric Oxide
|
Topics |
- Administration, Intravenous
- Adolescent
- Adult
- Anemia, Iron-Deficiency
(drug therapy, etiology)
- Female
- Ferric Compounds
(administration & dosage, adverse effects)
- Ferrosoferric Oxide
(administration & dosage, adverse effects)
- Humans
- Inflammatory Bowel Diseases
(complications)
- Male
- Middle Aged
- Retrospective Studies
- United States
- Young Adult
|